IDEAS home Printed from https://ideas.repec.org/b/elg/eebook/2780.html
   My bibliography  Save this book

Innovation in the Pharmaceutical Industry

Author

Listed:
  • Takuji Hara

Abstract

Innovation in the Pharmaceutical Industry traces the discovery and development of drugs in Japan and the UK both historically and sociologically. It includes sixteen case studies of major pharmaceutical developments in the twentieth century, encompassing, amongst others, beta-blockers, beta-stimulants, inhaled steroids and histamine H2-antagonists.

Individual chapters are listed in the "Chapters" tab

Suggested Citation

  • Takuji Hara, 2003. "Innovation in the Pharmaceutical Industry," Books, Edward Elgar Publishing, number 2780.
    • Handle: RePEc:elg:eebook:2780
    as

    Download full text from publisher

    File URL: https://www.elgaronline.com/view/9781843760504.xml
    Download Restriction: no
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Török, Ádám & Csuka, Gyöngyi, 2014. "Magyarország a nemzetközi innovációs versenyben az EU-csatlakozás után [Hungary s relative R+D+I performance in the EU - 10 years after its accession]," Közgazdasági Szemle (Economic Review - monthly of the Hungarian Academy of Sciences), Közgazdasági Szemle Alapítvány (Economic Review Foundation), vol. 0(4), pages 509-526.
    2. Santiago, Fernando & Alcorta, Ludovico, 2012. "Human resource management for learning through knowledge exploitation and knowledge exploration: Pharmaceuticals in Mexico," Structural Change and Economic Dynamics, Elsevier, vol. 23(4), pages 530-546.
    3. Arnaud Costinot & Dave Donaldson & Margaret Kyle & Heidi Williams, 2019. "The More We Die, The More We Sell? A Simple Test of the Home-Market Effect," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 134(2), pages 843-894.
    4. Wang, Kai & Hong, Jin & Marinova, Dora & Zhu, Liang, 2009. "Evolution and governance of the biotechnology and pharmaceutical industry of China," Mathematics and Computers in Simulation (MATCOM), Elsevier, vol. 79(9), pages 2947-2956.
    5. Jorge V. P鲥z-Rodr z & Beatriz G. L. Valcarcel, 2012. "Do product innovation and news about the R&D process produce large price changes and overreaction? The case of pharmaceutical stock prices," Applied Economics, Taylor & Francis Journals, vol. 44(17), pages 2217-2229, June.
    6. Baba, Yasunori & Walsh, John P., 2010. "Embeddedness, social epistemology and breakthrough innovation: The case of the development of statins," Research Policy, Elsevier, vol. 39(4), pages 511-522, May.
    7. Santiago-Rodriguez, Fernando, 2008. "Facing the Trial of Internationalizing Clinical Trials to Developing Countries: Some Evidence from Mexico," MERIT Working Papers 2008-023, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
    8. Reiko Aoki & Tomoko Saiki, 2005. "Implications of Product Patents : Lessons from Japan," Hi-Stat Discussion Paper Series d05-85, Institute of Economic Research, Hitotsubashi University.
    9. David Dranove & Craig Garthwaite & Manuel I. Hermosilla, 2020. "Expected Profits and The Scientific Novelty of Innovation," NBER Working Papers 27093, National Bureau of Economic Research, Inc.
    10. Alexandre Trigo, 2016. "Innovation in the Era of Experience: The Changing Role of Users in Healthcare Innovation," Journal of Entrepreneurship, Management and Innovation, Fundacja Upowszechniająca Wiedzę i Naukę "Cognitione", vol. 12(2), pages 29-51.
    11. Henry Adobor, 2012. "Ethical Issues in Outsourcing: The Case of Contract Medical Research and the Global Pharmaceutical Industry," Journal of Business Ethics, Springer, vol. 105(2), pages 239-255, January.
    12. Victor Oladapo & Godwin Onyeaso, 2013. "Tracing The Trajectory Of Industry Leader’S Drug Innovation Capability: The Amgen Corporation Case," Review of Business and Finance Studies, The Institute for Business and Finance Research, vol. 4(2), pages 69-77.

    Book Chapters

    The following chapters of this book are listed in IDEAS

    More about this item

    Keywords

    Economics and Finance; Social Policy and Sociology;

    JEL classification:

    • I1 - Health, Education, and Welfare - - Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:elg:eebook:2780. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Darrel McCalla (email available below). General contact details of provider: http://www.e-elgar.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.